Description
The cost of waiting for the clinic
A physician diagnoses heart failure, knows several drug classes are indicated, is not confident of the sequence, and refers — and the patient waits eleven weeks on no disease-modifying treatment at all. That pattern does more damage in practice than any incorrect drug choice, and it is entirely a confidence problem.
These 350 pages are written to remove it.
What to do on the day
The book is explicit where most texts are not: the two things that must happen at diagnosis, the one agent to start when only one can be started, and an honest account of what needs specialist input versus what merely feels safer to defer. Clinicians report this as the section that changed their practice fastest.
Realistic about constraints
Titration is taught against the limits that actually bite — a systolic of 96, a rising creatinine, a patient who cannot afford four agents, a formulary that does not stock one of them. That is the ordinary situation across much of the world and is treated as the default case rather than an exception.
Also covered
Phenotyping, decompensation and diuretic strategy, device candidacy at referral level, comorbidity, and referral timing — with the blunt point that referring late costs more outcome than any drug decision.
Suits
General physicians, family doctors, hospitalists, internal medicine trainees, and cardiac nurse specialists.
PDF, lifetime access, via CardiologyBooks.com.
Sequencing and titration in the real clinic
Heart failure management fails most often in the gap between starting therapy and reaching target dose. The book gives explicit sequencing for the four pillars, the order that suits the hypotensive patient, the order that suits the congested patient, and the intervals at which renal function and potassium actually need rechecking rather than the intervals convention suggests.
Preserved ejection fraction, and the patient who is not improving
A full section addresses HFpEF, where the diagnosis is uncertain and the evidence is younger, and a further section addresses the patient who remains symptomatic on optimal therapy — the point at which device therapy, rhythm intervention, iron replacement or advanced-therapy referral should be considered rather than another diuretic increase. Palliative and end-of-life discussion is included, because heart failure management includes knowing when to stop escalating.
